14 Jan 2025
ZERO Biotech, a clinical stage radiopharmaceutical company, was honored to present its radioligand therapy project at the prestigious Asian Financial Forum (AFF) in Hong Kong. The event served as a platform for ZERO Biotech to unveil the immense potential of radioligand therapy in transforming healthcare across Asia.
With great thanks for the invitation from The Hong Kong Trade Development Council, ZERO Biotech's CEO Mr. Clement Tam got the precious opportunity at the AFF to share with finance experts, industry leaders and investors with insights of the cutting-edge research and development efforts driving the future of radiopharmaceuticals in the region. Radioligand therapy represents a mature and proven approach in the treatment of cancer, offering new hope for patients and healthcare providers alike.
"Recently, there were big IPO and M&A in the nuclear medicine sector that were largely covered by finance and healthcare media in the west, but not much covered in Asia particularly in Hong Kong," said Clement. "This implies Asia is still lagging behind in the radiopharmaceutical sector, but we, ZERO Biotech, are working hard to catch up."
The AFF stands out as an iconic platform in the region that brings together prominent figures from government, finance, and business sectors worldwide for open conversations and the sharing of insights on the global economy, with a focus on an Asian perspective. It offered ZERO Biotech a unique stage to engage with key stakeholders and the financial community. The company's participation underscores its commitment to advancing the field of radiopharmaceuticals and bringing about positive change in patient care across the region.
ZERO Biotech looks forward to continuing its pioneering work in radioligand therapy, with a focus on innovation, collaboration, and improving healthcare outcomes for patients in Asia and beyond.